MétaCan
Menu
Back to cohort
Record W4412695793 · doi:10.1097/ju.0000000000004695

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study

2025· article· en· W4412695793 on OpenAlexaff
Bernhard J. Eigl, Arun Elangovan, Sunita Ghosh, Julian O. Kim, John Thoms, Myriam Bouchard, Michael Peacock, Neil Fleshner, Holly A. Campbell, É. Vigneault, F. Vincent, Alan So, Fabio Cury, Harvey Quon, Ryan Carlson, Carole Lambert, L.H. Klotz, Kim N., Michael Brundage, Michaël Pollak, L. Rebane, Leanne Chiu, Kerry S. Courneya, Nawaid Usmani

Bibliographic record

VenueThe Journal of Urology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMetabolism, Diabetes, and Cancer
Canadian institutionsCentre Hospitalier de l’Université de MontréalMcGill University Health CentreCentre Hospitalier Universitaire de SherbrookeUniversity of British ColumbiaDalhousie UniversityUniversity of TorontoUniversity of AlbertaHealth Sciences CentreCancerCare ManitobaSaskatchewan Cancer AgencyCentre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecSunnybrook Health Science CentreDr. H. Bliss Murphy Cancer CentreCentre hospitalier universitaire de QuébecNortheast Cancer CentreBC Cancer Agency
Fundersnot available
KeywordsMedicineMetforminPlaceboAndrogen deprivation therapyInternal medicineRandomized controlled trialMetabolic syndromeProstate cancerDiabetes mellitusGastroenterologyEndocrinologyObesityInsulinCancer

Abstract

fetched live from OpenAlex

PURPOSE: We investigated whether metformin decreases metabolic syndrome (MS) risk in patients with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). MATERIALS AND METHODS: In this phase 3, multicenter, double-blind, randomized controlled trial, normoglycemic patients with PCa planned for at least 9 months of ADT were randomized 2:1 to receive metformin 850 mg or placebo twice daily orally for 18 months. The primary objective was to compare proportions of MS at 18 months between the study arms. RESULTS: = .03). CONCLUSIONS: Metformin did not reduce the risk of MS in patients with PCa on ADT. However, significant improvements in body weight, waist circumference, and hemoglobin A1c suggest a potential role for metformin in reducing ADT-related complications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.026

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.317
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicMetabolism, Diabetes, and CancerFrench-language works237,207